October 28, 2020

WATCH: Catabasis Phase 3 PolarisDMD Trial Results (Webinar Recording)

We were disheartened to learn earlier this week that the results from the Catabasis Phase 3 trial for edasalonexent (PolarisDMD) did not meet its primary or secondary endpoints. On October 27, 2020, PPMD was joined by…

Learn More

October 26, 2020

Catabasis Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne

We are disheartened to learn today the results from the Catabasis Phase 3 trial for edasalonexent (PolarisDMD) did not meet its primary or secondary endpoints. The unfortunate results from the Catabasis study is yet another…

Learn More

October 2, 2020

Catabasis Shares October 2020 Newsletter

Catabasis Pharmaceuticals has shared the latest edition of their community newsletter which includes information from their presentations at the Congress of the World Muscle Society. The Phase 3 PolarisDMD trial and GalaxyDMD open-label extension trial…

Learn More

September 28, 2020

Catabasis Presents Information On Edasalonexent At 25th International Congress Of The World Muscle Society

Catabasis Pharmaceuticals today shared information on the edasalonexent program in Phase 3 development for Duchenne in poster presentations at the Virtual 25th International Congress of the World Muscle Society. The posters include new preclinical research…

Learn More

September 18, 2020

Catabasis Shares September 2020 Newsletter

Catabasis Pharmaceuticals has shared the latest edition of their community newsletter.  Their plan is to share top-line results from the Phase 3 PolarisDMD trial of edasalonexent with the Duchenne community later this year. As highlighted in…

Learn More

July 24, 2020

Catabasis Shares July 2020 Newsletter

Catabasis Pharmaceuticals has shared the latest edition of their community newsletter, which highlights the value of the North Star Ambulatory Assessment in Duchenne. Click here to download the PDF.

Learn More

May 14, 2020

Catabasis Shares May 2020 Newsletter

Catabasis Pharmaceuticals has shared the latest edition of their community newsletter, including updates on edasalonexent and data shared during a recent scientific poster session. Click here to download the PDF.

Learn More

March 26, 2020

Catabasis Shares March 2020 Newsletter

Catabasis Pharmaceuticals has shared the latest edition of their community newsletter, including information about edasalonexent and COVID-19, and responses to questions they have received. Click here to download the PDF.

Learn More

March 18, 2020

Catabasis Shares Update on Edasalonexent and COVID-19

Catabasis Pharmaceuticals has shared an update responding to questions about edasalonexent and COVID-19. To date, Catabasis has not identified any safety concerns related to COVID-19, and they continue to monitor the trial for the safety…

Learn More

February 26, 2020

Catabasis Shares February 2020 Newsletter

Catabasis shares the latest edition of their community newsletter, including an update on edasalonexent, as we approach Rare Disease Day. Click here to download (PDF).

Learn More